Outputs that scientists can test
The platform combines proprietary models with experimental validation to produce candidate targets, antibodies and protein sequences. Biologists use it without coding or building their own AI infrastructure.
Working with a company’s own research data
Customers can fine-tune private instances using proprietary data while retaining ownership. Converge’s work spans oncology, neurodegenerative and autoimmune diseases, including antibody design and improvements to protein manufacturing yield.